IMO-2125

IMO-2125 · Idera Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for IMO-2125, covering 2019-02-15 to 2022-08-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma [Phase 2]

See pricing